LONDON (Alliance News) - ReNeuron Group PLC said Monday that it has filed an investigational new drug application with the US Food and Drug Administration for a phase I/II clinical trial of its human retinal progenitor cell therapy candidate for retinitis pigmentosa.
Retinitis pigmentosa is a group of hereditary eye diseases that result in the loss of sight. The trial will take place at clinical centre Massachusetts Eye and Ear in Boston. It expects to be able to begin the trial in the second half of this year, subject to approvals.
"The proposed retinitis pigmentosa clinical trial initiates the company's clinical activities in the US, a very significant milestone in the development of ReNeuron as a global leader in the stem cell therapy field," said Chief Executive Officer Olav Hellebø in a statement.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Reneuron (RENE)